Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.46 |
| ▸ | OXTR | P30559 | 3/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PRLHR | P49683 | 7/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26951915 | 0.93 | KEAP1 (0.49) | KEAP1NFE2L2KLKB1OXTRAVPR2 | |
| SCHEMBL26951743 | 0.93 | KLKB1 (0.49) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL23743537 | 0.93 | KLKB1 (0.48) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL26952055 | 0.92 | KLKB1 (0.48) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL23743610 | 0.92 | KLK5 (0.49) | KLKB1KLK5ALB | |
| SCHEMBL26951558 | 0.91 | KLKB1 (0.47) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL23743518 | 0.91 | KLKB1 (0.46) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL26951937 | 0.90 | KLKB1 (0.47) | KEAP1NFE2L2KLKB1KLK5ALB | |
| SCHEMBL23743566 | 0.88 | KEAP1 (0.45) | KEAP1NFE2L2KLKB1OXTRAVPR2 | |
| SCHEMBL26951904 | 0.87 | CTSG (0.48) | KEAP1NFE2L2KLKB1KLK5ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | KEAP1 4411/4885NFE2L2 4563/4885KLKB1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.